NCT06362590|Unknown
Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors
1 other identifier
LV-SPIND-001
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredApr 2024
Brief Summary
The purpose of this study is to provide the option of Ladiratuzumab Vedotin treatment to eligible patients in studies SGNLVA-005.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 2, 2024
Completed10 days until next milestone
First Posted
Study publicly available on registry
April 12, 2024
CompletedLast Updated
June 17, 2025
Status Verified
June 1, 2025
First QC Date
April 2, 2024
Last Update Submit
June 16, 2025
Interventions
Eligibility Criteria
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Seagen Inc.lead
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 2, 2024
First Posted
April 12, 2024
Last Updated
June 17, 2025
Record last verified: 2025-06